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The effects of recombinant interleukin 1 alpha and beta, as 
well as recombinant interleukin 2, on human keratinocyte 
proliferation were studied in serum-containing as well as 
defined media. Both interleukin 1 preparations did not stim-
ulate keratinocyte growth; interleukin 2 also did not stimu-
late keratinocyte growth. To determine whether interleukin 
1 beta binds to keratinocytes, a cell membrane assay was 
developed for these cells. Iodinated interleukin 1 beta binds 
to keratinocytes with a kD of 6.2 nm and 2500 receptors per 
Both murine and human keratinocytes produce an inter-leukin 1 (IL-l)-like substance termed epidermal cell-derived thymocyte activating factor (ET AF) [1,2]. Whether this substance is identical to IL-l is still not clear, but ET AF appears to have functions similar to 
those of IL-l [3,4]. Other potential sources of IL-l in the human 
skin include macrophages and Langerhans cells (LC) [5,6]. In the 
presence of a foreign antigen, IL-l activates T cells and, in conjunc-
tion with interleukin 2 (IL-2), causes proliferation of these cells 
[7,8]. An IL-l-like substance has been documented in the skin in 
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KGM: keratinocyte growth medium 
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rIL-2: recombinant interleukin 2 
RjM-FITC: fluorescein isothiocyanate cOI~ugated rabbit anti-mouse 
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SDS: sodium dodecyl sulfate 
2D-PAGE: two-dimensional polyacrylamide gel electrophoresis 
2-ME: 2-mercaptoethanol 
cell. To determine the effects of interleukin 1 beta on protein 
synthesis, the molecular patterns of radiolabeled cell extracts 
of interleukin 1 beta-treated and nontreated keratinocytes 
were compared using two-dimensional polyacrylamide gel 
electrophoresis. No significant changes in the molecular pat-
tern of newly synthesized proteins were detected. Finally, 
none of these lymphokines induced HLA-DR expression by 
keratinocytes. ] Invest Dermatol 93: 121-126, 1989 
psoriasis [9]. Indeed, several investigators have suggested that an 
IL-l-like substance enhances murine as well as human keratinocyte 
proliferation in vitro [10,11]. By contrast, when injected into the 
skin in vivo, IL-l does not cause acanthosis [12] . 
An IL-2-like substance, termed keratinocyte-derived T-cell 
growth factor, has recently been described in human skin [13,14]. 
Interleukin 2 is the actual proliferative signal for T lymphocytes and 
induces IL-2 receptors on these cells [8]. 
Because products, such as gamma interferon, of immune compe-
tent cells, influence the growth ofkeratinocytes, as well as inducing 
the synthesis of new proteins [15,16], we examined the effects of 
two other cytokines, IL-l and IL-2, on human keratinocytes. 
MATERIALS AND METHODS 
Lymphokines, Labeling with Monoclonal Antibodies (mAb) 
and Fluorescence Microscopy The recombinant IL-l (rIL-l) 
alpha and beta were a gift of Dr. A. Allison (Syntex Corp. Palo Alto, 
CA) and were biologically active as measured in the thymocyte 
proliferation assay and the EL-4 conversion assay (E. Eugui, per-
sonal communication). The recombinant IL-2 (rIL-2) was obtained 
from both Cetus, Inc., Emeryville, CA, and Cellular Products, Inc., 
Buffalo, NY. The latter preparation comes diluted in 2% fetal calf 
serum (FCS). Both r1L-2 products demonstrated biological activity 
in that they stimulated human peripheral blood lymphocyte prolif-
eration. The antiHLA-DR mAb (L243) was obtained from Becton 
Dickinson, Mountain View, CA, as was the isotype control mAb, 
anti-Leu-2b. The endotoxin concentration in the Cetus rIL-2 prep-
aration was less than 0.1 ngjml. 
One million epidermal cells were stained for 30 min with the 
murine mAb diluted in 5% heat-inactivated FCS in phosphate-
buffered saline (PBS) containing 0.02% sodium azide (AZ), as de-
scribed previously [17] . The cells were washed with 5% FCSjPBSj 
AZ, stained with fluorescein isothiocyanate-conjugated rabbit 
anti-mouse IgG (R/M-FITC] (ICN lmmunobiologicals, Lisle, IL) 
for 30 min, washed with and then resuspended in 5% FCSjPBSj 
AZ. The number of fluorescent cells was determined by fluores-
cence microscopy or fluorescent-activated cell sorter (FACS) analy-
sis [17] . 
Cell Culture Conditions Single cell suspensions of healthy skin 
were prepared from skin obtained at surgery [18]. Trimmed skin 
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was cut into 1 X 5 cm strips and split-cut with a Castroviejo kerato-
tome set at 0.1 mm. The resulting slices were treated for 35 min at 
37"C with 0.3% trypsin plus 0.1 % ethylenediaminetetraacetic acid 
(EDTA) in GNK (0.8% NaCI, 0.04% KCL, 0.1 % glucose, 0.084% 
NaHC03, pH 7.3). Other keratinocyte cultures, derived from 
breast skin, were obtained from Clonetics Corp., San Diego, CA. 
Keratinocytes were grown using three different methods of culture. 
In the first, dispersed cells were suspended in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% heat-inactivated 
FCS, 50 ,ug/ml gentamicin and 2 mM L-glutamine (complete me-
dium), and seeded at 1.8-2 X 106 cells/3.5 cm collagen-coated 
Petri dish (Lux, Miles Scientific, Naperville, IL) [18]. For culture in 
serum-free medium, the method described by Ham and Boyce was 
used [19,20]. The cells were trypsinized and seeded at 3 X 104 cells/ 
3.5-cm Petri dish in keratinocyte growth medium (KGM) (Clo-
netics) for use in the experiments. Using the third method, adult 
keratinocytes were grown in a fully defined medium (keratinocyte 
defined medium [KDM], Clonetics), without bovine pituitary ex-
tract (BPE). Both KGM and KDM have a short shelf-life and were 
used within 2 weeks of arrival as recommended by the manufac-
turer. In both the complete medium and KGM the cell viability was 
above 95%, whereas in KDM the cell viability was lower and varied. 
Unless otherwise indicated, the lymphokine(s) was added 24 h after 
seeding the cells and readded biweekly with each medium change. 
Cell Harvesting and Cell Counts At the times indicated, cul-
tures were washed once with PBS, 1 ml of 0.3% trypsin/O.l % 
EDTA in GNKadded, and the plates incubated for 10 min at 37 °C. 
The detached cells were transferred to tubes, the plates rinsed once 
with complete medium to remove adherent cells, and this rinse 
combined with the 1-ml aliquots already in the tubes. Using a 
hemacytometer, the cells were counted immediately to determine 
total number of cells per plate, and an aliquot was di luted with 
trypan blue to document the numbers of viable cells. 
Labeling of Cells with 35S-Methionine and One- and Two-
Dimensional Polyacrylamide Gel Electrophoresis (1 and 
2D-PAGE) Keratinocytes were isolated and cultured in complete 
medium as described above. The cultures were incubated with 
(35S]methionine (10,uCi/ml) for 18 h in methionin-free DMEM 
and harvested using trypsin. After addition of serum to stop trypsin 
activity, the cells were collected by centrifugation, washed once 
with PBS, resuspended in 90,u1 PBS containing 10 J1g/ml DNase I, 
10,ug/ml RNase, 1 mM phenyl methane sulphonyl fluoride, 
1 mM N-methylmaleimide, 5 mM Mg2S04 , and 10 ,u11O% Triton 
x-100 in PBS was added with mixing. After centrifugation, the 
supernatants were carefully removed as the Triton-soluble fraction. 
The pellet was reextracted successively with 50 mM citrate buffer, 
pH 2.65 (prekeratin fraction), in the cold and 2% sodium dodecyl 
sulfate (SDS) , 2.5% 2-mercaptoethanol (2-ME) in Tris, pH 6.8 
(sample buffer), at 100°C for 10 min. Where necessary, protein 
fractions were brought to 2% SDS, 2.5% 2-ME by addition of an 
equal volume of twice the sample buffer and boiled for 10 min. 
One-D-PAGE was carried out using the discontinuous system of 
Laemmli [21] at a constant current density of200 mA/cm2 until the 
tracking dye (bromophenol blue) reached the bottom of the gel. 
Lane loads were adjusted to the same total radioactivity. Two-D-
PAGE was performed using isoelectric focusing (IEF) with pH 5 - 7 
ampholines (LKB, Broma, Sweden) in the first dimension and the 
discontinuous SDS buffer system in the second [22]. All gels were 
fixed in 50% methanol, 10% acetic acid water, soaked in EnHance, 
washed for 30 min in water, dried, juxtaposed to Kodak X-Omai: 
film, and stored in the dark at -70 ° C for 6 - 72 h, depending on the 
radioactivity in the gel, and the films developed. Newly synthesized 
proteins in the IL-1 treated cultures were com.pared visually with 
those in mock treated cultures. 
Keratinocyte Particulate Preparation Cultured human kera-
tinocytes were removed from 3.5-cm Petri dishes and homoge-
nized, using a Polytron (Brinkman, Westbury, NY) (setting #4 for 
30 sec), to a 5% homogenate (wt/vol) in 0.05 M phosphate buffer 
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(81 mM Na+, 9 mM K+, 0.09 mM Ca2+, 0.5 mM Mg+, pH 7.43 at 
4°C) [23]. Each homogenate was washed by diluting it with 20 ml 
of phosphate buffer and centrifuging it at 50,000 g for 15 min in a 
BeckmanJ2-21 centrifuge (Beckman Instruments, Inc., Fullerton, 
CA). The cell homogenates were washed by dilution and centrifu-
gation to remove any endogenous substances that might interfere 
with the (1 251]rIL-l binding assay. The supernatant was discarded 
and the pellet resuspended in the appropriate volume of phosphate 
buffer. A O.l-ml aliquot was saved for analysis of protein content by 
the method of Lowry et al [24] . 
Receptor Binding Studies For the standard cell-membrane 
assays, cells were cultured either in serum-containing medium or in 
KGM and then switched to KDM 2 days before harvesting. At 
confluence, the cells were scraped off, and aliquots of the washed 
tissue suspension were added to two sets of duplicate 2-ml plastic 
centrifuge tubes that were pretreated with 1 % bovine serum albu-
min (BSA) and allowed to air dry for 12 h before the experiment 
[23]. One set (total binding) contained varying (125I]rIL-1 beta con-
centrations. The other set (nonspecific binding) contained varying 
(1 251]rIL-1 beta concentrations and 100 nm unlabeled rIL-l beta in 
1 ml phosphate buffer. The binding of [1251]rIL_l beta was studied 
between 0.025 and 10 nm. Both sets of tubes (total and nonspecific 
binding) were routinely incubated at 4°C for 60 min to ensure 
steady-state conditions. The suspensions were qiluted with 4 ml of 
cold buffer and filtered immediately through glass fiber filters 
(Whatman GF /B, 2.5 cm). Each of the tubes was rinsed again with 
4 ml ice-cold buffer, which was poured over the appropriate filter in 
a 30-well filter box (Steed Engineering Co., Palo Alto, CA). All 
filters were washed an additional two times with 4 ml of ice-cold 
buffer. The filters were air-dried and the membrane-bound radioac-
tivity estimated by gamma spectrometry (Beckman Instruments, 
Inc., Fullerton, CA) with a counting efficiency of 43%. Specific 
(1 251]rIL-1 binding for each substrate concentration (expressed as 
nmol [125I]rIL-1 / mg protein) was calculated by subtracting the non-
specific from the total binding. 
RESULTS 
Effect of rIL-l Alpha and Beta as well as rIL-2 on Keratino-
cyte Growth The effects of rIL-1 alpha and beta on keratinocyte 
growth were tested using various media. In medium-containing 
serum, all concentrations of IL-1 beta tested (1 - 100 ng/ ml) inhib-
ited growth in a dose-dependent fashion (Fig 1). One hundred 
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Figure 1. The effect of nanogram concentrations of rIL-l beta on keratino-
eyte growth in serum-containing medium. The doses of rIL-l beta used were 
1- 100 ng/ml. The Iymphokine was added 48 h after seeding the cells. The 
IL-l beta significantly inhibits keratinocyte growth at 10-100 ng/ml. The 
SEM was less than 20% for each time point. A similar pattern of growth 
inhibition was seen in a second, separate experiment. 
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ng/ ml rIL-1 beta inhibited cell proliferation about threefold by day 
6 after addition of the cytokine. 
In KGM, the rlL-l beta at low concentrations (2.5 ng/ml) did 
not significantly affect cell numbers/Petri dish of logarithmically 
growing keratinocytes over a 7-day period (not shown). At higher 
concentrations (100 ng/ml), however, rlL-1 beta again markedly 
inhibited keratinocyte growth (not shown). The rIL-l alpha at 
10 ng/ml also did not affect keratinocyte growth under these con-
ditions (not shown). 
Because keratinocytes grown in serum-containing medium or in 
KGM may already be proliferating maximally, the effect of the 
lymphokines on cells grown in KDM also was examined. Keratino-
cytes grown in KGM were switched to KDM for 2 days, and then 
reseeded in KDM at 3 X 104 cells/plate. Twenty-four hours later, 
10 ng/ml rlL-1 alpha or beta was added (Fig 2). At the various 
time-points indicated, total numbers of cells/plate, as well as viable 
cells/plate, were determined. As can be seen, rIL- l alpha and beta 
did not significantly affect either the total number of cells/plate or 
the number of viable cells/plate. 
To determine if pi cog ram quantities of IL-l alpha or IL-l beta 
would stimulate growth of keratinocytes, the cells were incubated 
with 1, 5, 25, and 125 pg/ml doses of these Iymphokines in KDM. 
Cell numbers were determined on the days indicated after addition 
of the proteins (Table I). No stimulation by either Iymphokine 
could be documented. 
The rIL-2 preparation from Cellular Products comes diluted in 
2% FCS and we routinely dilute the stock rIL-2 from Cetus in 
human serum to prevent binding to the plastic. Therefore, we de-
termined the effects of low concentrations of protein (e.g., serum, 
BSA) in this system of culture using KDM (Table I). Low concen-
trations of either human serum alone or BSA alone stimulated kera-
tinocyte growth under these conditions of culture. 
To determine the effect of rIL-2 on keratinocyte proliferation, 
the cells grown in either KDM or KGM were incubated with 12.5, 
125, and 625 pg/ml rIL-2. No stimulation of growth could be 
demonstrated vis-a-vis the controls cultured in the appropriate 
amounts of protein (Table II). In a separate experiment, even higher 
doses of rIL-2 (up to 1.25 ng/ml) were used and again demonstrated 
no effect on keratinocyte growth (not shown). 
Finally, keratinocytes were grown in KGM in the presence of 
between 12.5 -625 pg/ml rIL-2. These cells also showed no differ-
ence in their growth rates as compared with controls (not shown). 
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Figure 2. The effect of rIL-1 alpha (10 ng/ml) and beta (10 ng/ml) on 
keratinocyte growth. The il/sert documents average total number of cells/ 
plate. The error bars indicate standard error of duplicate experiments. This 
data is representative of a pattern seen in three separate experiments. 
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Table I. Effect of Various Proteins on Proliferation of 
Keratinocytes Grown in KDM 
Days in 
Culture Addition 
5 0.01 % HS6 
10 0.01 % HS 
5 0.0040/0 BSA 
10 0.0040/0 BSA 
5 1 pg/mIIL-l alpha 
5 5 pg/ml rIL-l alpha 
5 25 pg/ml rlL-l alpha 
5 125 pg/ml rIL-lalpha 
6 1 pg/ml 1L-l beta 
6 5 pg/mIIL-l beta 
6 25 pg/ml 1L-l beta 
6 125 pg/ml 1L-l beta 
• The n = 4 for each value. 
I HS = human serum. 
Cell Number 
(0/0 Control)' 
142c 
123 
187' 
255' 
116 
108 
108 
116 
93 
100 
87 
106 
' These numbers are statistically different from the controls with a p value less than 
0.005. 
Binding of (125I]rIL-1 Beta to Cnltured Keratinocytes Be-
cause the absence of a growth stimulatory effect of rIL-l beta on 
keratinocytes could be explained by a lack of cell-surface receptors 
for this protein, we studied specific binding of rIL-l beta to kerati-
nocytes. The rIL-1 beta was labeled with 1251, using Bolton Hunter 
reagent according to the method described previously, and then 
used to measure rIL-1 beta binding to cultured, human keratinocyte 
cell membranes [23]. Saturation of the rIL-l binding sites was mea-
sured at [I25I]rIL-1 beta concentrations between 0.025 -10 nm. Un-
labeled rIL-l beta was used to define nonspecific binding and maxi-
mally inhibited [125I]rIL_1 beta binding at a concentration of 
100 nm. Saturable, specific (125I]rIL-l beta binding was approxi-
mately 70% of the total binding at 10 nm and approximately 80% 
of the total binding at 0.025 nm (125I]rIL-l beta. Analysis of these 
saturation isotherms gave a K J of 6.2 nm and a Bmox of 1.0 pmole/ 
mg protein for the cell-membrane preparation (Fig 3). Approxi-
mately the same number of receptors/cell were demonstrated re-
gardless of whether the cells were cultured in KGM/KDM or in 
serum-containing medium. 
Table II. Effect of rlL-2 on the Proliferation of Keratinocytes 
Grown in KDM and KGM 
Days in Concentration 
Culture of rIL-2 (pg/ml) 
Control' 
5 12.5' 
125 
625 
Control 
10 12.5 
125 
625 
Control ' 
5 12.5 
125 
625 
Control 
10 12.5 
125 
625 
Medium 
KDM 
KGM 
Number of Cells/Plate 
2.2 ± 0.146 X 10' 
2.2 ± 0.35 X 10' 
1.7 ± 0.1 X 10' 
1.9 ± 0 X 10' 
1.2 ± 0 X 10' 
1.6 ± 0.14 X 10' 
1.5±0.14 XI0' 
1.3 ± 0.2 X 10' 
7.3 ± 0.7 X 10' 
5.6 ± 0.6 X 10' 
6.1 ± 0.35 X 10' 
6.2 ± 1.0 X 10' 
2.4 ± 0.14 X 105 
2.6 ± 0.14 X 105 
2.5 ± 0.14 X 105 
2.3 ± 0.1 X 105 
• The control cells received as much human serum (0.5 X 10-4%) as was present in 
the highest concentration of r1L-2 added to the lymphokine-treated cultures. 
I These counts represent the average of duplicate plates ± SEM. The numbers of cells 
per plate did not show a significantly different trend between control and rIL-2-
treated cultures. 
' 12.5 pgjml rIL-2 = 0.1 U j m!. 
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Figure 3. Binding of rlL-1 beta to the particulate fraction prepared from 
cultured keratinocytes. Each point represents an independent measurement. 
K J is the dissociation constant of the binding reaction and Rn is the concen-
tration ofIL-1 binding sites in the particulate fraction. The points were fitted 
directly to the binding equation by the method of least squares using a 
simplex algorithm iterative procedure [3'71. Equal weight was given to each 
experimental value. The ordinate plots lL-1 bound as pmole/mg protein. 
Molecular Pattern of the Proteins Synthesized by Kel'atino-
cytes After rIL-l Beta Treatment To determine whether rlL-1 
beta affected the protein synthesis of keratinocytes the cells were 
radiolabeled 3 days after the addition of lymphokine (0.5 and 
5.0 ng/ml) and the cells harvested 18 hours later. Synthesis of total 
proteins was not affected significantly in rIL-1 beta-treated cultures 
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at the doses tested. The (35SJmethionine-labeled cellular proteins 
synthesized after rIL-1 beta treatment were separated into Triton-
soluble and Triton-insoluble fractions and analyzed using 1 and 
2D-PAGE. Both Triton-soluble and Triton-insoluble proteins 
showed no major difference in their molecular patterns at either of 
the two concentrations of rlL-1 beta tested as compared with con-
trols. The 2D-PAGE gels of the Triton-soluble proteins are shown 
(Fig 4). 
Expression of HLA-DR Antigen by Keratinocytes After 
rIL-l Alpha and Beta as well as rIL-2 Treatment Because 
gamma interferon induces the expression of HLA-DR antigen on 
keratinocytes, we examined whether rIL-1 alpha or beta had a simi-
lar effect. Cells were incubated with various concentrations of rIL-1 
beta (1, 10, 100 ng/ml) in growth medium. On days 2, 4, and 6, 
representative cultures were harvested, and the expression ofHLA-
DR antigen was determined using immunofluorescence staining. 
No HLA-DR antigen expression could be detected on the keratino-
cytes at any of these time-points (not shown) . In parallel cultures, all 
of these concentrations of rIL-1 beta inhibited keratinocyte growth 
in a dose-dependent fashion. The tffect of rIL-1 alpha (10 ng/ml) 
on HLA-DR expression by keratinocytes was ascertained on day 8 
after cytokine addition in KGM. The rIL-1 alpha also did not induce 
HLA-DR expression (not shown). 
The capacity of rIL-2 (1.3 ng/ml; 10 U /m.1) to induce the ex-
pression of HLA-DR was examined on day 10 after addition of the 
cytokine. No expression of DR antigen was found (not shown). 
DISCUSSION 
Isolated particulate matter from cultured human keratinocytes dem-
onstrate specific, saturable (125IJrIL-1 beta binding. This binding 
was both temperature- and time-dependent, and steady-state condi-
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Figure 4. Two-dimensional polyacrylamide gels of labeled extracts of 
rlL-1 beta-treated keratinocytes show no major changes in the patterns of 
triton soluble protein(s). a: 0.5 ng/ml rIL-l beta, b: 5 ng/ml rIL-l beta. Gels 
from the control, untreated keratinocytes are depicted in c. 
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tions were reached in 40 min at 4 0 C. Saturation studies at steady-
state conditions revealed a major population of binding sites with K. 
in the nanometer range and an average of about 2500 binding sites/ 
cell. The value of the K. we have obtained is larger than that re-
ported for murine T lymphocytes or fibroblasts [25,26]. 
U sing three different types of media, we have been unable to 
verify that rIL-l alpha or beta stimulates keratinocyte proliferation. 
The experiments by Gilchrest and Sauder [11] were not performed 
using recombinant material, and it is conceivable that other factors 
in their preparation were responsible for the increase in keratinocyte 
growth . Ristow [10], who also reported an increase in keratinocyte 
proliferation, actually only measured thymidine incorportion into 
DNA, rather than cell numbers. Thus, it is conceivable that rIL-l 
activates uptake of[3H]thymidine or initiates DNA synthesis with-
out causing mitosis. Further in Ristow's system, murine keratino-
cytes were used, and it is possible that murine cells react differently 
to IL-l than do human keratinocytes, as is the case for gamma 
interferon induction of HLA-DR antigen. Although gamma inter-
feron induces HLA-DR antigen on normal human keratinocytes, 
this Iymphokine does not induce Ia antigen expression on normal , 
muring keratinocytes in vitro (G. Krueger, personal communica-
tion, and V. Morhenn, unpublished data). 
Because keratinocytes secrete ETAF, it is conceivable that this 
autocrine secretion masks the effects of the added, exogenous pro-
tein. This explanation is unlikely as the amount ofET AF secreted by 
keratinocytes would result in insignificant concentrations in the 
volume of medium used in these cultures. Moreover, the rIL-l beta 
causes no major changes in the molecular pattern of Triton-soluble 
or Triton-insoluble keratinocyte proteins synthesized in vitro, sug-
gesting that no major new protein is produced. It also seems un-
likely that IL-l induces keratinocytes to secrete a growth inhibitory 
factor that would counteract a putative mitogenic effect of the IL-l 
itself. However, we cannot entirely rule out the possibility that a 
growth inhibitory substance, which is not a protein, is induced by 
IL-1. Finally, this study confirms an earlier report that IL-1 and IL-2 
do not induce HLA-DR antigen expression and expands this finding 
to include both rIL-1 alpha and beta, as well as, rIL-2 [27]. 
In psoriasis, a disease of keratinocyte hyperproliferation, abnor-
malities in im.munologic factors, such as cytokines, have been im-
plicated [28 - 30]. Cyclosporine, a drug that has known immuno-
modulatory effects , decreases the secretion of IL-1 and IL-2 by 
lymphocytes and also \?roduces a dramatic improvement in many 
cases of psoriasis [31,32J. Interestingly, this drug has no direct effect 
on the proliferation of normal, human keratinocytes in vitro, but 
does effect their growth when keratinocytes are in a hyperprolifera-
tive stage in murine skin [33,34] . Furthermore, cyclosporine does 
inhibit proliferation of normal murine keratinocytes as well as 
transformed murine and human keratinocytes in vitro [35] . 
Because rIL- l does not stimulate proliferation of keratinocytes, 
but may activate DNA synthesis in these cells, we also determined 
the effect 'of rIL-2 on keratinocyte proliferation. Recombinant IL-2 
also does not enhance keratinocyte growth in vitro . This in vitro 
documentation is consistent with the recent report that when rIL-2 
is injected into humans, no acanthosis of the skin is observed [36]. 
Furthermore, these authors could not demonstrate IL-2 receptors 
on keratinocytes in situ. Possibly, the exacerbation of psorias is after 
rIL-2 administration is due to an effect on the mononuclear leuko-
cytes found in the dermal infiltrate or another dermal constituent 
(e. g., endothelial cells or fibroblasts) [36] . Based on our study, the 
exacerbating effect of rIL-2 in psoriasis does not appear to be due to a 
direct growth-promoting effect of rIL-2 on keratinocytes. 
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